Known targets — ChEMBL curated mechanism
GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHMGCRMMP1MMP13MMP7MMP8PTGS1PTGS2ileSpolrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9128728 | 0.94 | CA1 (0.52) | CA1TSHRCYP3A4NFKB1NPSR1 | |
| Lithium Ion SCHEMBL6832458 | 0.94 | — | — | |
| SCHEMBL15771695 | 0.94 | CA1 (0.52) | CA1TSHRCYP3A4NFKB1NPSR1 | |
| SCHEMBL8747822 | 0.94 | CA1 (0.52) | CA1TSHRCYP3A4NFKB1NPSR1 | |
| SCHEMBL2322447 | 0.94 | — | — | |
| SCHEMBL8660757 | 0.94 | CA1 (0.52) | CA1TSHRCYP3A4NFKB1NPSR1 | |
| SCHEMBL17512350 | 0.94 | CA1 (0.52) | CA1TSHRCYP3A4NFKB1NPSR1 | |
| SCHEMBL8386165 | 0.94 | CA1 (0.52) | CA1TSHRCYP3A4NFKB1NPSR1 | |
| SCHEMBL8660240 | 0.94 | CA1 (0.52) | CA1TSHRCYP3A4NFKB1NPSR1 | |
| SCHEMBL11318291 | 0.94 | CA1 (0.52) | CA1TSHRCYP3A4NFKB1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120142528-A | Method for simultaneously determining beta-hydroxy beta-methylbutyrate and amino acid in food | 上海体育大学 | 2025-06-13 | — | — | CN | claimed |
| CN-119899005-A | Environment-friendly dust collection limestone powder shield grouting material and environment-friendly preparation method thereof | 济南市城建材料开发服务中心 | 2025-04-29 | — | — | CN | claimed |
| CN-119867154-A | Milk for promoting calcium absorption and preparation method thereof | 内蒙古蒙牛乳业（集团）股份有限公司 | 2025-04-25 | — | — | CN | claimed |
| CN-222670481-U | Cooling device is used in production of calcium methylbutyrate | 连云港盛和生物科技有限公司 | 2025-03-25 | — | — | CN | claimed |
| CN-119563768-A | Application of beta-hydroxy-beta-methylbutyrate calcium in improving production performance of horses | 新疆农业大学 | 2025-03-07 | — | — | CN | claimed |
| CN-118415357-B | Protein composition effective in promoting protein intake | 浙江衡美健康科技股份有限公司 | 2024-11-15 | — | — | CN | claimed |
| CN-118844586-A | Method for improving surimi gel characteristics by utilizing beta-hydroxy-beta-calcium methylbutyrate | 大连工业大学 | 2024-10-29 | — | — | CN | claimed |
| CN-116024846-B | Preparation method of natural-color high-stiffness straw base paper | 华邦古楼新材料有限公司 | 2024-08-09 | — | — | CN | claimed |
| CN-118415357-A | Protein composition for promoting thickening of muscle fibers after strength training | 浙江衡美健康科技股份有限公司 | 2024-08-02 | — | — | CN | claimed |
| CN-118191147-A | Method for determining beta-hydroxy-beta-calcium methylbutyrate in milk and dairy products | 杭州海关技术中心 | 2024-06-14 | — | — | CN | claimed |
| US-7789980-B2 | Preparation of ammonium dinitroamide (ADN) crystals, ADN crystals and energetic composites containing them | SNPE MATERIAUX ENERGETIQUES (FR) | 2010-09-07 | — | — | US | claimed |
| US-20090176860-A1 | ZOFENOPRIL CALCIUM | GENERICS [UK] LIMITED (INCORPORATED IN THE UNITED KINGDOM) (GB) | 2009-07-09 | — | — | US | claimed |
| US-20090090441-A1 | Preparation of Ammonium Dinitroamide (ADN) Crystals, ADN Crystals and Energetic Composites Containing Them | SNPE MATERIAUX ENERGETIQUES (FR) | 2009-04-09 | — | — | US | claimed |
| EP-2041083-A1 | ZOFENOPRIL CALCIUM | Merck Generics (UK) Limited (GB) | 2009-04-01 | — | — | EP | claimed |
| US-7495052-B2 | Method for the production of polymerized nanoparticles and microparticles by ternary agent concentration and temperature alteration induced immiscibility | BAUSCH & LOMB INCORPORATED (US) | 2009-02-24 | — | — | US | claimed |
| WO-2007138352-A1 | ZOFENOPRIL CALCIUM | GENERICS (UK) LIMITED (GB) | 2007-12-06 | — | — | WO | claimed |
| WO-2006137855-A2 | METHOD FOR THE PRODUCTION OF POLYMERIZED NANOPARTICLES AND MICROPARTICLES BY TERNARY AGENT CONCENTRATION AND TEMPERATURE ALTERATION INDUCED IMMISCIBILITY | BAUSCH & LOMB INCORPORATED (US) | 2006-12-28 | — | — | WO | claimed |
| WO-2006137856-A2 | METHOD FOR THE PRODUCTION OF NANOPARTICLES AND MICROPARTICLES BY TERNARY AGENT CONCENTRATION AND TEMPERATURE ALTERATION INDUCED IMMISCIBILITY | BAUSCH & LOMB INCORPORATED (US) | 2006-12-28 | — | — | WO | claimed |
| US-20060057215-A1 | Method for the production of nanoparticles and microparticles by ternary agent concentration and temperature alteration induced immiscibility | BAUSCH & LOMB INCORPORATED | 2006-03-16 | — | — | US | claimed |
| US-20060057222-A1 | Method for the production of polymerized nanoparticles and microparticles by ternary agent concentration and temperature alteration induced immiscibility | BAUSCH & LOMB INCORPORATED | 2006-03-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176860-A1 | ZOFENOPRIL CALCIUM | CACNA1C, CA2, CACNA1S | CA1 291/4885TSHR 4808/4885CYP3A4 892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.